Completed PHASE1 INTERVENTIONAL 3-arm NCT03404817

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

Sponsor: Embera NeuroTherapeutics, Inc.

Interventions New formulation EMB-001 Original formulation EMB-001

Updated 5 times since 2018 Last updated: Jun 7, 2018 Started: Mar 1, 2018 Primary completion: Jun 7, 2018 Completion: Jun 7, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cocaine Use Disorder and is currently completed. Embera NeuroTherapeutics, Inc. leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Feb 2018 — Jul 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Embera NeuroTherapeutics, Inc.
National Institute on Drug Abuse (NIDA)

Data source: Embera NeuroTherapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Long Beach, United States